BRCA2 and breast carcinoma: As a cancer treatment drug, olaparib is first defined as the HR deficient tumor treatment, and it is fully approved by FDA for serous ovarian cancer and breast cancer treatment with germline BRCA1 or BRCA2 mutations [9,31,32].